• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发和验证用于美国前列腺癌患者的预期寿命计算器。

Development and validation of a life expectancy calculator for US patients with prostate cancer.

机构信息

Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.

出版信息

BJU Int. 2022 Oct;130(4):496-506. doi: 10.1111/bju.15740. Epub 2022 Apr 24.

DOI:10.1111/bju.15740
PMID:35373440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9474626/
Abstract

OBJECTIVE

To develop and validate an accurate, usable prediction model for other-cause mortality (OCM) in patients with prostate cancer diagnosed in the United States.

MATERIALS AND METHODS

Model training was performed using the National Health and Nutrition Examination Survey 1999-2010 including men aged >40 years with follow-up to the year 2014. The model was validated in the Prostate, Lung, Colon, and Ovarian Cancer Screening Trial prostate cancer cohort, which enrolled patients between 1993 and 2001 with follow-up to the year 2015. Time-dependent area under the curve (AUC) and calibration were assessed in the validation cohort. Analyses were performed to assess algorithmic bias.

RESULTS

The 2420 patient training cohort had 459 deaths over a median follow-up of 8.8 years among survivors. The final model included eight predictors: age; education; marital status; diabetes; hypertension; stroke; body mass index; and smoking. It had an AUC of 0.75 at 10 years for predicting OCM in the validation cohort of 8220 patients. The final model significantly outperformed the Social Security Administration life tables and showed adequate predictive performance across race, educational attainment, and marital status subgroups. There is evidence of major variability in life expectancy that is not captured by age, with life expectancy predictions differing by 10 or more years among patients of the same age.

CONCLUSION

Using two national cohorts, we have developed and validated a simple and useful prediction model for OCM for patients with prostate cancer treated in the United States, which will allow for more personalized treatment in accordance with guidelines.

摘要

目的

开发和验证一种准确且可用的预测模型,用于预测在美国诊断为前列腺癌的患者的其他原因死亡率(OCM)。

材料与方法

使用 1999-2010 年全国健康和营养调查(NHANES)的数据进行模型训练,该研究纳入了年龄>40 岁的男性,随访至 2014 年。在前列腺、肺、结肠和卵巢癌症筛查试验(PLCO)前列腺癌队列中对模型进行验证,该队列纳入了 1993 年至 2001 年期间的患者,随访至 2015 年。在验证队列中评估时间依赖性曲线下面积(AUC)和校准。分析用于评估算法偏差。

结果

在 2420 例患者的训练队列中,在幸存者的中位随访 8.8 年期间有 459 人死亡。最终模型包括 8 个预测因子:年龄、教育程度、婚姻状况、糖尿病、高血压、中风、体重指数和吸烟。在 8220 例患者的验证队列中,该模型在预测 10 年内 OCM 的 AUC 为 0.75。最终模型显著优于社会保障管理局生命表,并在种族、教育程度和婚姻状况亚组中表现出良好的预测性能。有证据表明预期寿命存在重大差异,而不仅仅由年龄决定,同一年龄的患者之间预期寿命的预测差异可达 10 年或以上。

结论

使用两个全国性队列,我们开发并验证了一种用于美国治疗的前列腺癌患者 OCM 的简单而有用的预测模型,这将使我们能够根据指南更个性化地治疗患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46e/9546054/a6412c08428a/BJU-130-496-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46e/9546054/f2bc96a9a07b/BJU-130-496-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46e/9546054/4ab819d5d7b5/BJU-130-496-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46e/9546054/a6412c08428a/BJU-130-496-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46e/9546054/f2bc96a9a07b/BJU-130-496-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46e/9546054/4ab819d5d7b5/BJU-130-496-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c46e/9546054/a6412c08428a/BJU-130-496-g002.jpg

相似文献

1
Development and validation of a life expectancy calculator for US patients with prostate cancer.开发和验证用于美国前列腺癌患者的预期寿命计算器。
BJU Int. 2022 Oct;130(4):496-506. doi: 10.1111/bju.15740. Epub 2022 Apr 24.
2
Successful external validation of a model to predict other cause mortality in localized prostate cancer.用于预测局限性前列腺癌其他原因死亡率的模型的成功外部验证。
BMC Med. 2016 Feb 9;14:25. doi: 10.1186/s12916-016-0572-z.
3
External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.基于索赔数据的前列腺癌特异性合并症指数的外部验证:用于预测前列腺癌男性预期寿命的工具。
J Urol. 2019 Sep;202(3):518-524. doi: 10.1097/JU.0000000000000287. Epub 2019 Aug 8.
4
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.国际前列腺癌分期协作组基于疾病特异性死亡率数据制定和验证非转移性前列腺癌临床预后分期系统。
JAMA Oncol. 2020 Dec 1;6(12):1912-1920. doi: 10.1001/jamaoncol.2020.4922.
5
Predicting 7-year mortality for use with evidence-based guidelines for Prostate-Specific Antigen (PSA) testing: findings from a large prospective study of 123 697 Australian men.预测用于前列腺特异性抗原(PSA)检测循证指南的7年死亡率:来自对123697名澳大利亚男性的大型前瞻性研究的结果
BMJ Open. 2018 Dec 14;8(12):e022613. doi: 10.1136/bmjopen-2018-022613.
6
Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.预测前列腺癌男性患者的预期寿命
Eur Urol. 2015 Nov;68(5):756-65. doi: 10.1016/j.eururo.2015.03.020. Epub 2015 Mar 26.
7
8
National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.美国预期寿命有限的老年男性中前列腺癌筛查的国家趋势:需要更多共享决策的证据。
Cancer. 2014 May 15;120(10):1491-8. doi: 10.1002/cncr.28600. Epub 2014 Feb 12.
9
Screening for prostate cancer.前列腺癌筛查
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3.
10
Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.韩国高级别前列腺癌风险计算器的开发与外部验证:在亚洲队列中与两种西方风险计算器的比较。
PLoS One. 2017 Jan 3;12(1):e0168917. doi: 10.1371/journal.pone.0168917. eCollection 2017.

引用本文的文献

1
Adaption of the Memorial Sloan Kettering Cancer Center Nomograms for the Prediction of Prostate Cancer-specific Death in Sweden: A Population-based Cohort Study.纪念斯隆凯特琳癌症中心列线图在瑞典预测前列腺癌特异性死亡中的应用:一项基于人群的队列研究
Eur Urol Open Sci. 2025 Jul 14;78:41-50. doi: 10.1016/j.euros.2025.06.003. eCollection 2025 Aug.
2
Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era.主动监测时代预期寿命有限男性前列腺癌的过度治疗
JAMA Intern Med. 2025 Jan 1;185(1):28-36. doi: 10.1001/jamainternmed.2024.5994.
3
Artificial intelligence-based personalized clinical decision-making for patients with localized prostate cancer: surgery versus radiotherapy.

本文引用的文献

1
Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration.利用自动化电子健康记录评分估算在退伍军人健康管理局诊断患有前列腺癌的男性的预期寿命。
Urology. 2021 Sep;155:70-76. doi: 10.1016/j.urology.2021.05.056. Epub 2021 Jun 15.
2
Other and All-Cause Mortality among Men Diagnosed with Prostate Cancer in the PLCO Trial.在 PLCO 试验中被诊断患有前列腺癌的男性的其他和全因死亡率。
J Urol. 2021 May;205(5):1372-1378. doi: 10.1097/JU.0000000000001531. Epub 2020 Dec 22.
3
Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool.
基于人工智能的局限性前列腺癌患者个性化临床决策:手术与放疗
Oncologist. 2024 Dec 6;29(12):e1692-e1700. doi: 10.1093/oncolo/oyae184.
4
Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer.局限性前列腺癌立体定向体部放疗后基线自我报告的疲劳与总生存的关联
Front Oncol. 2022 Dec 23;12:1015264. doi: 10.3389/fonc.2022.1015264. eCollection 2022.
利用患者报告的因素预测局限性前列腺癌男性患者因其他原因导致的 10 年死亡风险:工具的开发。
PLoS One. 2020 Dec 7;15(12):e0240039. doi: 10.1371/journal.pone.0240039. eCollection 2020.
4
Patient Reported vs Claims Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer.基于患者报告和索赔的健康指标在前列腺癌男性生命预期建模中的比较。
J Urol. 2021 Feb;205(2):434-440. doi: 10.1097/JU.0000000000001355. Epub 2020 Sep 10.
5
Predictably unequal: understanding and addressing concerns that algorithmic clinical prediction may increase health disparities.可预见的不平等:理解并解决有关算法临床预测可能加剧健康差异的担忧。
NPJ Digit Med. 2020 Jul 30;3:99. doi: 10.1038/s41746-020-0304-9. eCollection 2020.
6
Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration.退伍军人健康管理局诊断前列腺癌患者的预期寿命估计。
Urol Oncol. 2020 Sep;38(9):734.e1-734.e10. doi: 10.1016/j.urolonc.2020.05.015. Epub 2020 Jul 13.
7
Claims-Based Approach to Predict Cause-Specific Survival in Men With Prostate Cancer.基于索赔数据的方法预测前列腺癌男性患者特定病因生存率
JCO Clin Cancer Inform. 2019 Mar;3:1-7. doi: 10.1200/CCI.18.00111.
8
The c-index is not proper for the evaluation of $t$-year predicted risks.C 指数不适合评估 $t$ 年预测风险。
Biostatistics. 2019 Apr 1;20(2):347-357. doi: 10.1093/biostatistics/kxy006.
9
Successful external validation of a model to predict other cause mortality in localized prostate cancer.用于预测局限性前列腺癌其他原因死亡率的模型的成功外部验证。
BMC Med. 2016 Feb 9;14:25. doi: 10.1186/s12916-016-0572-z.
10
Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.预测前列腺癌男性患者的预期寿命
Eur Urol. 2015 Nov;68(5):756-65. doi: 10.1016/j.eururo.2015.03.020. Epub 2015 Mar 26.